Being Mortal

Surgeon, writer, and public health researcher Atul Gawande tackles the unpleasant subject of death in Being Mortal, a book that looks at how we currently handle end-of-life care and how it could be improved.
             ...
July 15th, 2015
0

Purchasing Medical Innovation

Written by health economist James C. Robinson, Purchasing Healthcare Innovation examines how we can slow the growth of healthcare spending without destroying medical innovation—a timely topic as the medtech industry continues to grapple with the effects of healthcare reform.
...
July 15th, 2015
0

Innovation Breakdown

Joseph V. Gulfo, MD, a veteran of the medtech industry who previously served as president of MELA Sciences, will stoke your anger at regulators and financiers in Innovation Breakdown, a chronicle of what it takes to bring breakthrough medical products to patients.
...
July 15th, 2015
0

MD+DI's picks for required summer reading for medtech professionals.

Whether you kick back in a lawn chair, beach chair, or hammock, we're betting that at some point this summer you'll find yourself looking for a book to help you while away the hours of a lazy summer afternoon. Our suggestion: Forgo those mindless mystery novels in favor of something a little meatier that will help you stay on top of your craft. 

Here are our picks for what medtech professionals should be reading this summer.

...
July 15th, 2015
0

Johnson & Johnson's medical device and diagnostics business continues to disappoint analysts. Will an acquisition or two help save the day?

Arundhati Parmar

Johnson & Johnson reported 2nd quarter earnings Tuesday, and the medical device and diagnostics segment underwhelmed analysts again.

Globally, the medical devices segment had revenue of $6.36 billion, down 12.2% over the same period a year ago. Even excluding the effects of currency fluctuations, revenue fell 4%. Analysts had expected the diversified healthcare company to garner $6.44 billion in its devices business in the second quarter.

In fact, the segment has underperformed the broader market for at least the last six quarters, according to Danielle Antalffy, an analyst with healthcare investment bank...

July 15th, 2015
0

Executives spouted lofty rhetoric about disrupting healthcare on J&J’s Q2 earnings call, but some analysts seem skeptical of the company’s ability to innovate.

Jamie Hartford

Johnson & Johnson believes the time is ripe for a shakeup in healthcare, and it wants to get in on the action.

“I've been in healthcare long enough to have heard over and over again that technology was going to disrupt the industry beyond recognition,” group worldwide chairman Sandy Peterson told analysts during the company’s Q2 earnings call on July 14. “But today, maturing technology, scientific advances, and global healthcare reform are combining to make disruption a reality.”

Peterson explained that the world’s largest...

July 15th, 2015
0

Telemedicine is going to be the wave of the future. Here are some facts that explain why. 

Arundhati Parmar

Earlier this year, the Centers for Medicare and Medicaid Services expanded the coverage of telemedicine for Medicare beneficiaries, and bills have been introduced in Congress, including the bipartisan Medicare Telehealth Parity Act, to recognize the power that telemedicine has to bring...

July 14th, 2015
0

Medical device developers should focus on these five outcomes to compete in today’s market.

Steve McPhilliamy

It used to be that healthcare delivery was procedure- and fee-for-service-based, with physicians reimbursed for the number of procedures or services they conducted in the medical environment. Today, reimbursement has shifted to an outcome-based model, making the number of procedures and services less important than the resulting outcome. This changing model, driven by payers’ growing focus on aligning reimbursement with things of greater value, such as patients’ health and treatment efficacy, offers zero reimbursement for repeat visits to physicians for recurrent or similar problems stemming from treatment complications. It’s less about how many times a procedure...

July 13th, 2015
0

We asked medical device designers what concepts they hope to integrate into their products over the next five years. Here's what they had to say.

Jamie Hartford

The highly regulated medtech industry is notoriously slow to adopt new technologies, opting instead to wait until the kinks are worked out before incorporating them into its designs. We asked medical device makers to consider what concepts they hope to integrate into their products over the next five years. Here's what they had to say:

(click to enlarge)

 

Learn more about developing next-generation medical devices at...
July 13th, 2015
0

Many believed Medtronic would slow down its M&A activity after buying Covidien. Has that happened?

Arundhati Parmar

A recurring sentiment from medtech experts after Medtronic announced that it would buy Covidien for $50 billion was one of apprehension.

It's not good for startups that one of the most active buyers was taking on such a major acquisition, they said. Venture capitalists and others bemoaned the fact that the new Medtronic would probably be slower in making acquisitions. They were also concerned that the megamerger necessarily meant the demise of Covidien as a buying entity. Covidien too was a prolific investor. 

But Monday's announcement from Medtronic — it is...

July 13th, 2015
0